A LinkedIn post from Orasis Pharmaceuticals highlights the company’s support of Presbyopia Awareness Month by featuring prescriber Dámaris Raymondi, O.D., FAAO. The post points to an “exciting new category” of presbyopia eye drops and directs readers to safety information and educational resources on treatment benefits and risks.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The content suggests Orasis is emphasizing clinical engagement and real‑world prescriber perspectives to build credibility for its presbyopia therapy. For investors, this focus on awareness and education may indicate an ongoing commercial push to expand adoption in the large U.S. presbyopia population, with potential implications for prescription volume and long‑term market positioning in vision care therapeutics.